Literature DB >> 1662626

Phagocyte uptake and transport of azithromycin.

P J McDonald1, H Pruul.   

Abstract

Azithromycin achieves high concentrations in phagocytic cells and in fibroblasts. The newer macrolides also have this property but the intracellular penetration of azithromycin in relation to extracellular concentration is particularly notable. As a weak base, azithromycin is thought to concentrate in lysosomes of phagocytes and fibroblasts but many in vitro factors such as pH and temperature also affect the uptake process. Uptake of azithromycin by polymorphonuclear leucocytes results in an intracellular/extracellular concentration ratio of approximately 40 after one hour of incubation. Intraphagocytic antimicrobial activity has been demonstrated but is rather less than might be anticipated from the intracellular concentrations that are reached. Importantly, the high antibiotic levels found intracellularly do not appear to disrupt normal phagocyte function. Although azithromycin levels in the blood are low soon after administration, tissue concentrations are high and sustained. It appears that fibroblasts serve as a reservoir of drug in tissue, allowing activity against organisms and possibly transferring antibiotic to phagocytic cells for activity against intracellular pathogens and delivery to infection sites.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1662626     DOI: 10.1007/bf01975835

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  21 in total

1.  Comparison of the in-vitro effect of several macrolides on the oxidative burst of human neutrophils.

Authors:  M T Labro; J el Benna; C Babin-Chevaye
Journal:  J Antimicrob Chemother       Date:  1989-10       Impact factor: 5.790

Review 2.  The importance of penetration of antimicrobial agents into cells.

Authors:  J C Schwab; G L Mandell
Journal:  Infect Dis Clin North Am       Date:  1989-09       Impact factor: 5.982

Review 3.  Commentary. Lysosomotropic agents.

Authors:  C de Duve; T de Barsy; B Poole; A Trouet; P Tulkens; F Van Hoof
Journal:  Biochem Pharmacol       Date:  1974-09-15       Impact factor: 5.858

4.  Azithromycin in the treatment of sexually transmitted disease.

Authors:  O Steingrimsson; J H Olafsson; H Thorarinsson; R W Ryan; R B Johnson; R C Tilton
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

5.  Intraphagocytic activity of erythromycin, roxithromycin and azithromycin.

Authors:  D Milatovic
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-01       Impact factor: 3.267

6.  Intracellular accumulation of azithromycin by cultured human fibroblasts.

Authors:  R P Gladue; M E Snider
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

7.  Influence of bacterial-antibiotic interactions on subsequent antimicrobial activity of alveolar macrophages.

Authors:  W L Hand; N L King-Thompson; J D Johnson
Journal:  J Infect Dis       Date:  1984-02       Impact factor: 5.226

8.  Azithromycin compared with cephalexin in the treatment of skin and skin structure infections.

Authors:  S B Mallory
Journal:  Am J Med       Date:  1991-09-12       Impact factor: 4.965

9.  Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells.

Authors:  M B Carlier; A Zenebergh; P M Tulkens
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790

10.  An in vitro investigation of the intracellular bioactivity of amoxicillin, clindamycin, and erythromycin for Staphylococcus aureus.

Authors:  R Anderson; G Joone; C E van Rensburg
Journal:  J Infect Dis       Date:  1986-03       Impact factor: 5.226

View more
  34 in total

1.  Tailoring Antibiotic Treatment to Host Immune Status: The Host, Not the Drug, Determines Outcome.

Authors:  Peter J. McDonald; Hendrik Pruul
Journal:  Curr Infect Dis Rep       Date:  2001-08       Impact factor: 3.725

Review 2.  Review of macrolides and ketolides: focus on respiratory tract infections.

Authors:  G G Zhanel; M Dueck; D J Hoban; L M Vercaigne; J M Embil; A S Gin; J A Karlowsky
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Clinical Efficacy of Azithromycin as an Adjunctive Therapy to Non-Surgical Periodontal Treatment of Periodontitis: A Systematic Review and Meta-Analysis.

Authors:  Antonio Renatus; Jörg Herrmann; Antje Schönfelder; Fabian Schwarzenberger; Holger Jentsch
Journal:  J Clin Diagn Res       Date:  2016-07-01

4.  Disease severity, debridement approach and timing of drug modify outcomes of adjunctive azithromycin in non-surgical management of chronic periodontitis: a multivariate meta-analysis.

Authors:  Nithya Jagannathan; Aneesha Acharya; Ong Yi Farn; Kar Yan Li; Luigi Nibali; George Pelekos
Journal:  BMC Oral Health       Date:  2019-04-27       Impact factor: 2.757

Review 5.  Non-surgical periodontal therapy supplemented with systemically administered azithromycin: a systematic review of RCTs.

Authors:  Sabrina L Buset; Nicola U Zitzmann; Roland Weiger; Clemens Walter
Journal:  Clin Oral Investig       Date:  2015-06-12       Impact factor: 3.573

6.  Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy.

Authors:  P Matzneller; S Krasniqi; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

7.  Azithromycin impact on neutrophil oxidative metabolism depends on exposure time.

Authors:  H Levert; B Gressier; I Moutard; C Brunet; T Dine; M Luyckx; M Cazin; J C Cazin
Journal:  Inflammation       Date:  1998-04       Impact factor: 4.092

Review 8.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  In vitro activities of new macrolides and rifapentine against Brucella spp.

Authors:  J A García-Rodríguez; J L Muñoz Bellido; M J Fresnadillo; I Trujillano
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

10.  Relationship between antibiotic concentration in bone and efficacy of treatment of staphylococcal osteomyelitis in rats: azithromycin compared with clindamycin and rifampin.

Authors:  T O'Reilly; S Kunz; E Sande; O Zak; M A Sande; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.